Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 12, 2010, Pages 5315-5319

  Fasciani, Alessandro ^a   Quilici, Paolo ^a   Biscaldi, Ennio ^a   Flamini, Marina ^b   Fioravanti, Anna ^b   Orlandi, Paola ^b   Oliviero, Jolanda ^a   Repetti, Felice ^a   Bandelloni, Roberto ^a   Danesi, Romano ^b   Simoncini, Tommaso ^b   Bocci, Guido ^b  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5;

ADULT; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENDOMETRIOSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PERITONEAL DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCINTIGRAPHY;

EID: 78650052373     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0397     Document Type: Article

References (20)

1. Bianconi L, Hummelshoj L, Coccia ME, Vigano P, Vittori G, Veit J, Music R, Tomassini A, D'Hooghe T 2007 Recognizing endometriosis as a social disease: the European Union-encouraged Italian Senate approach. Fertil Steril 88:1285-1287
2. Howard FM 2003 Chronic pelvic pain. Obstet Gynecol 101:594-611
3. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C 2003 Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999-1017
4. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, Susini C 2004 Molecular signaling of somatostatin receptors. Ann NY Acad Sci 1014:121-131
5. Modlin IM, Pavel M, Kidd M, Gustafsson BI 2010 Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31:169-188
6. Appetecchia M, Baldelli R 2010 Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 29:19
7. Green VL, Richmond I, Maguiness S, Robinson J, Helboe L, Adams IP, Drummond NS, Atkin SL 2002 Somatostatin receptor 2 expression in the human endometrium through the menstrual cycle. Clin Endocrinol (Oxf) 56:609-614 (Pubitemid 34595728)
8. Schulz S, Schmitt J, Weise W 2003 Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gynecol Oncol 89:385-390
9. Fasciani A, Repetti F, Binda GA, Puntoni M, Meroni MG, Bocci G 2010 Endometriosis index: a software-derived score to predict the presence and severity of the disease. J Endometriosis 2:79-86
10. Alì G, Donati V, Loggini B, Servadio A, Dell'Omodarme M, Prati MC, Camacci T, Lucchi M, Melfi F, Mussi A, Fontanini G 2008 Different estrogen receptor β expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 39:1465-1473
11. Flamini MI, Sanchez AM, Goglia L, Tosi V, Genazzani AR, Simoncini T 2009 Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells. Mol Hum Reprod 15:675-685
12. Howard FM 2009 Endometriosis and mechanisms of pelvic pain. J Minim Invasive Gynecol 16:540-550
13. Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL 2005 Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493-1498
14. Palii SS, Afzal A, Shaw LC, Pan H, Caballero S, Miller RC, Jurczyk S, Reubi JC, Tan Y, Hochhaus G, Edelhauser H, Geroski D, Shapiro G, Grant MB 2008 Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor. Invest Ophthalmol Vis Sci 49:5094-5102
15. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD 1997 Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 3:265-272
16. Bocci G, Culler MD, Fioravanti A, Orlandi P, Fasciani A, Colucci R, Taylor JE, Sadat D, Danesi R, Del Tacca M 2007 In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur J Clin Invest 37:700-708
17. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R 1997 Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 15:77-86
18. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC 2001 Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab 86:2161-2169
19. Gambineri A, Patton L, De Iasio R, Cantelli B, Cognini GE, Filicori M, Barreca A, Diamanti-Kandarakis E, Pagotto U, Pasquali R 2005 Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. J Clin Endocrinol Metab 90: 3854-3862
20. Preleviæ GM, Wurzburger MI, Balint-Periæ L, Nesiæ JS 1990 Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet 336:900-903